Evidence map›Paper›PMID 33615991›Full record

ArticlemAbs

Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes.

Pavel Bondarenko, Andrew C Nichols, Gang Xiao, Rachel Liuqing Shi, Pik Kay Chan, Thomas M Dillon, Fernando Garces, David J Semin, Margaret S Ricci

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pavel BondarenkoAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Andrew C NicholsAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Gang XiaoAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Rachel Liuqing ShiAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Pik Kay ChanAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Thomas M DillonAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Fernando GarcesDepartment of Therapeutics Discovery, Amgen Research, Amgen Inc , Thousand Oaks, CA, USA.
David J SeminAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Margaret S RicciAttribute Sciences, Process Development, Amgen Inc , Thousand Oaks, CA, USA.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic proteins including antibodies and Fc-fusion proteins undergo a large number of chemical modifications during cell culture, purification, storage and in human circulation. They are also exposed to harsh conditions during stress studies, including elevated temperature, extremes of pH, forced oxidation, physiological pH, UV light to assess the possible degradation pathways and suitability of methods for detecting them. Some of these modifications are located on residues in binding regions, leading to loss of binding and potency and classified as critical quality attributes. Currently, criticality of modifications is assessed by a laborious process of collecting antibody fractions from the soft chromatography techniques ion exchange and hydrophobic interaction chromatography and characterizing the fractions one-by-one for potency and chemical modifications. Here, we describe a method for large-scale, parallel identification of all critical chemical modifications in one experiment. In the first step, the antibody is stressed by one or several stress methods. It is then mixed with target protein and separated by size-exclusion chromatography (SEC) on bound antibody-target complex and unbound antibody. Peptide mapping of fractions and statistical analysis are performed to identify modifications on amino acid residues that affect binding. To identify the modifications leading to slight decreases in binding, competitive SEC of antibody and antigen mixtures was developed and described in a companion study by Shi et al, where target protein is provided at lower level, below the stoichiometry. The newly described method was successfully correlated to crystallography for assessing criticality of chemical modifications and paratope mapping. It is more sensitive to low-level modifications, better streamlined and platform ready.

Indexed as

Antigen-Antibody ComplexChromatography, GelEpitope MappingEpitopesAntibodies, MonoclonalAntibody SpecificityAntigen-Antibody ReactionsAntigensBinding Sites, AntibodyImmunoglobulin GPeptide MappingProtein StabilityStructure-Activity RelationshipAntibodies, MonoclonalAntigen-Antibody ComplexAntigensEpitopesImmunoglobulin Gantibody-antigen bindingantibody-antigen complexchemical modificationsmonoclonal antibodyparatope mappingpeptide mappingsize exclusion chromatographyTherapeutic proteinvolcano plot

Identifiers

PMID33615991
PMCPMC7899697
OpenAlexW3130606862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.